{"prompt": "['14 QUALITY CONTROL AND QUALITY ASSURANCE', 'To ensure compliance with Good Clinical Practice (GCP) and all applicable regulatory', 'requirements, ITI or its designee may conduct a quality assurance audit of the study site', 'records and regulatory agencies may conduct a regulatory inspection at any time during', 'or after the study. In the event of an audit or inspection, the investigator (and institution)', 'must agree to grant the auditor(s) and inspector(s) direct access to all relevant', 'documents and to allocate their time and the time of their staff to discuss any', 'findings/relevant issues. Responsibility for the accuracy, completeness, and reliability of', 'the study data presented to the sponsor lies with the investigator generating the data.', 'Intra-Cellular Therapies, Inc. Confidential', '65 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']['15 ETHICS/PROTECTION OF HUMAN SUBJECTS', '15.1', 'Ethical Standard', '15.2', 'Independent Ethics Committee or Institutional Review Board', 'Federal regulations and the International Conference on Harmonisation (ICH) guidelines', 'require that approval be obtained from an Institutional Review Board (IRB) or', 'Independent Ethics Committee (IEC) before participation of human patients in research', 'studies. Before study onset, the protocol, informed consent, advertisements to be used', 'for the recruitment of study patients, and any other written information regarding this', \"study to be provided to the patient or the patient's legal guardian must be approved by\", 'the IRB/IEC. Documentation of all IRB/IEC approvals and of the IRB/IEC compliance', 'with ICH harmonised tripartite guideline E6(R1): GCP will be maintained by the study', 'site and will be available for review by the sponsor or its designee.', 'All IRB/IEC approvals should be signed by the IRB/IEC chairman or designee and must', 'identify the IRB/IEC name and address; the clinical protocol by title, protocol number, or', 'both; and the date approval or a favorable opinion was granted.', 'The investigator is responsible for providing written summaries of the progress and', 'status of the study at intervals not exceeding 1 year or otherwise specified by the', 'IRB/IEC. The investigator must promptly supply the sponsor or its designee, the', 'IRB/IEC, and, where applicable, the institution, with written reports on any changes', 'significantly affecting the conduct of the study or increasing the risk to patients.', '15.3', 'Ethical Conduct of the Study', 'The study will be performed in accordance with the ethical principles that have their', 'origin in the Declaration of Helsinki, ICH GCP, and all applicable regulations.', '15.4', 'Institutional Review Board', 'The protocol, informed consent form(s), recruitment materials, and all patient materials', 'will be submitted to the IRB/IEC and local regulatory authorities (where applicable) for', 'review and approval. Approval of both the protocol and the consent form must be', 'obtained before any patient is enrolled. Any amendment to the protocol will require', 'review and approval by the IRB/IEC as well as local regulatory authorities, before the', 'changes are implemented in the study.', 'Intra-Cellular Therapies, Inc. Confidential', '66 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']['15.5', 'Informed Consent Process', '15.6', 'Patient Information and Consent', 'Informed consent is a process that is initiated prior to the individual agreeing to', 'participate in the study and continues throughout study participation. Extensive', 'discussion of risks and possible benefits of study participation will be provided to', 'patients and their families, if applicable. A consent form describing in detail the study', 'procedures and risks will be given to the patient. Consent forms will be IRB/IEC-', 'approved, and the patient is required to read and review the document or have the', 'document read to him or her. The investigator or designee will explain the research', 'study to the patient and answer any questions that may arise. The patient will sign the', 'informed consent document prior to any study-related assessments or procedures.', 'Patients will be given the opportunity to discuss the study with their surrogates or think', 'about it prior to agreeing to participate. They may withdraw consent at any time', 'throughout the course of the study. A copy of the signed informed consent document', 'will be given to patients for their records. The rights and welfare of the patients will be', 'protected by emphasizing to them that the quality of their clinical care will not be', 'adversely affected if they decline to participate in this study.', 'The consent process will be documented in the clinical or research record.', 'A written informed consent in compliance with US Title 21 Code of Federal Regulations', '(CFR) Part 50 shall be obtained from each patient before entering the study or', 'performing any unusual or nonroutine procedure that involves risk to the patient. An', 'informed consent template may be provided by the sponsor to clinical study sites. If any', 'institution-specific modifications to study-related procedures are proposed or made by', 'the study site, the consent should be reviewed by the sponsor, its designee, or both', 'before IRB/IEC submission. Once reviewed, the consent will be submitted by the', 'investigator to his or her IRB/IEC for review and approval before the start of the study.', 'If the ICF is revised during the course of the study, all active participating patients must', 'sign the revised form.', 'Before recruitment and enrollment, each prospective patient or his or her legal guardian', 'will be given a full explanation of the study and be allowed to read the approved ICF.', 'Once the investigator is assured that the patient/legal guardian understands the', 'implications of participating in the study, the patient/legal guardian will be asked to give', 'consent to participate in the study by signing the ICF.', 'The investigator shall retain the signed original ICF(s) and give a copy of the signed', 'original form to the patient or legal guardian.', 'Intra-Cellular Therapies, Inc. Confidential', '67 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']\n\n###\n\n", "completion": "END"}